New research validates what our IBD community has long known: Crohn’s disease affects far more than just physical symptoms. This comprehensive study documents the real emotional, social, and psychological impacts of living with IBD, offering important insights for patients and caregivers alike.

The IBD treatment market is projected to reach $42 billion by 2035, driven by advances in targeted therapies and biologics. This growth could mean more treatment options, personalized care, and potentially lower costs for patients with Crohn’s disease and ulcerative colitis.

The STOMP-II clinical trial shows promising results for AVB-114, a bioactive implant that improved healing rates for Crohn’s perianal fistulas without significant side effects. This could offer new hope for patients seeking alternatives to surgery and complex treatments.

Research reveals that alcohol’s impact on IBD symptoms varies significantly from person to person, with some experiencing flares while others tolerate moderate consumption. Understanding your individual response and discussing alcohol use with your healthcare team can help you make informed decisions about drinking with inflammatory bowel disease.

Sanofi’s Phase 2b Crohn’s trial shows promising results with reduced inflammation and improved quality of life. We explore what this targeted approach could mean for the IBD community and future treatment options.

Sanofi’s oral medication SAR441566 showed promising Phase 2 results for moderate-to-severe Crohn’s disease patients who hadn’t responded well to standard treatments. While still in early research stages, this potential new option offers hope for better symptom control with the convenience of oral dosing.